Biopharma company GSK plc (LSE:GSK) (NYSE:GSK) announced on Wednesday that it has received US Food and Drug Administration (FDA) approval for Arexvy (respiratory syncytial virus vaccine, adjuvanted), the world's first respiratory syncytial virus (RSV) vaccine for older adults.
Arexvy was approved for the prevention of lower respiratory tract disease (LRTD) caused by RSV in individuals aged 60 and over.
The vaccine was shown to have an efficacy of 82.6% against RSV-LRTD in adults aged 60 years and older, meeting the primary endpoint of the pivotal AReSVi-006 phase III trial. Efficacy against severe RSV-LRTD, which is defined as an RSV-associated LRTD episode preventing normal, everyday activities, was 94.1%.
Arexvy is expected to launch in the United States before the 2023/24 RSV season.
A final regulatory decision is anticipated in Europe in the coming months. Regulatory reviews are also ongoing in Japan and several other countries.
Replicate Bioscience begins phase one trial of RBI-4000 vaccine
Moderna and Immatics form strategic collaboration to develop new oncology therapies
Pfizer and BioNTech's Omicron XBB.1.5-adapted COVID-19 vaccine receives positive CHMP opinion in EU
Valneva's chikungunya vaccine moves forward with Health Canada's review
Allucent Awarded BARDA Contract to Support Acceleration of Next-Generation COVID-19 Booster Vaccines
Anixa Biosciences advances ovarian cancer CAR-T trial with third patient
GC Biopharma signs MoU with GC Biopharma for co-production of Euvichol
GC Biopharma partners with Eubiologics for joint cholera vaccine production
GSK's Shingrix shows 100% efficacy against shingles in Chinese adults
Pfizer's Abrysvo receives FDA approval for pregnant individuals to prevent RSV in infants
Arcturus' mRNA manufacturing partner ARCALIS receives USD115m in grants from the Japanese government
Roquefort Therapeutics boosts patent portfolio with PCT Filing